Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorUniversitaire Ziekenhuizen KU Leuven
About this trial
Investigation of the mechanisms of persistent SARS-CoV-2 associated olfactory dysfunction (OD) in patients with well-documented olfactory function. The investigators plan to collect olfactory cleft biopsies and cytobrushes in COVID-19 patients and controls.
Eligibility criteria
Qualifiers
Olfactory Dysfunction group: Presence of evident OD (Parosmia, Threshold-Discrimination-Identification (TDI)-score ≤24, Subjective abnormal quantitative olfactory function; measured by a visual analogue score (VAS) of smell impairment ≥5/10
Control group: No OD (TDI-score >30.5.)
Disqualifiers
Presence of concomitant nasal mucosal pathology that might affect olfactory function or bias the study investigations
Use of anticoagulation therapy
Allergy to local anesthetics
Trial design
Treatments tested in this trial
- Biopsy and Cytobrush
Treatment groups
240 Participants
are divided into 2 treatment groupsSponsors and collaborators
Universitaire Ziekenhuizen KU Leuven
Lead sponsor
University Hospital, Geneva
Collaborator
Max Planck Research Unit for Neurogenetics
Collaborator
University Hospital Carl Gustav Carus
Collaborator
University of Zurich
Collaborator
Source ClinicalTrials.gov